Objectives: To compare the efficacy and safety of algenpantucel-L [Hyper-Acute-Pancreas algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy alone in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: To date, immunotherapy has not been shown to benefit patients with borderline resectable or locally advanced unresectable

Key Points Question Does the effectiveness of cancer immunotherapy vary between female and male patients with advanced melanoma? Findings In this population-based cohort study that included 1369 patients 65 years of age or older with advanced melanoma, a significant sex difference in overall mortality was seen among patients treated with nivolumab plus ipilimumab combination immunotherapy, with women having a 2-fold higher mortality risk than their male counterparts. Meaning This study suggests that the sex of the patient must be considered when designing a treatment strategy for patients with metastatic melanoma to optimize outcomes.

No abstract

No abstract